Amgen Aranesp Not Affected By Medicare Reimbursement Changes; Sales Up 113%
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen's Aranesp (darbepoetin) sales are thus far unaffected by changes in Medicare Part B reimbursement, Exec VP-Global Commercial Operations George Morrow said
You may also be interested in...
Medicare Overpaying For EPO In Dialysis, IG Says; Costs Expected To Rise Through 2004
The largest providers' acquisition costs for the top 10 dialysis drugs are between 12% and 68% below the Medicare reimbursement rate, an IG report says. The switch to an ASP-based model may help some providers but hurt others.
Medicare Overpaying For EPO In Dialysis, IG Says; Costs Expected To Rise Through 2004
The largest providers' acquisition costs for the top 10 dialysis drugs are between 12% and 68% below the Medicare reimbursement rate, an IG report says. The switch to an ASP-based model may help some providers but hurt others.
J&J Draws Line On Procrit Pricing; Will Not Match Amgen Aranesp 40% Discounts
Procrit sales are the one weak spot in a strong quarter overall. J&J is moving away from its previous policy of retaining a "level playing field" between Procrit and Aranesp pricing; the strategy now is to have a "reasonably level playing field."